Your browser is no longer supported. Please, upgrade your browser.
Settings
ASLN ASLAN Pharmaceuticals Limited daily Stock Chart
ASLN [NASD]
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-0.86 Insider Own- Shs Outstand37.99M Perf Week-5.56%
Market Cap71.04M Forward P/E- EPS next Y-0.49 Insider Trans- Shs Float36.90M Perf Month-1.58%
Income- PEG- EPS next Q-0.07 Inst Own8.68% Short Float0.08% Perf Quarter57.14%
Sales- P/S- EPS this Y80.70% Inst Trans- Short Ratio0.20 Perf Half Y-7.88%
Book/sh0.41 P/B4.56 EPS next Y-75.00% ROA- Target Price- Perf Year-45.80%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.35 - 8.18 Perf YTD-7.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.14% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low434.29% ATR0.15
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)46.81 Volatility5.22% 8.42%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close1.93
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume138.80K Price1.87
Recom2.30 SMA20-3.90% SMA502.35% SMA2004.02% Volume59,286 Change-3.11%
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Jun-25-20 08:50AM  
Jun-19-20 05:50PM  
Jun-11-20 12:00PM  
Jun-04-20 09:46PM  
May-11-20 05:34AM  
May-07-20 05:50PM  
Apr-20-20 08:56AM  
Apr-13-20 04:21AM  
Mar-26-20 12:00PM  
Mar-18-20 05:18AM  
Feb-24-20 02:05AM  
Feb-20-20 05:50PM  
Feb-10-20 05:45PM  
Feb-04-20 05:45PM  
Jan-28-20 10:39AM  
Jan-27-20 11:30AM  
Jan-15-20 04:34PM  
08:22AM  
Jan-14-20 08:53AM  
Jan-13-20 12:00PM  
Jan-06-20 12:04PM  
Dec-18-19 09:58AM  
06:57AM  
Dec-05-19 06:22PM  
Dec-03-19 02:29PM  
07:59AM  
01:00AM  
Dec-02-19 01:34PM  
12:50PM  
07:51AM  
02:07AM  
Nov-22-19 08:18AM  
01:30AM  
Nov-11-19 12:36PM  
07:09AM  
03:21AM  
Nov-08-19 09:00AM  
Nov-06-19 11:00AM  
10:34AM  
Oct-31-19 03:37AM  
Oct-22-19 02:45AM  
Oct-18-19 03:35AM  
Oct-02-19 02:30AM  
Sep-30-19 02:35AM  
Sep-19-19 03:50AM  
Sep-10-19 05:14AM  
Aug-27-19 06:00AM  
Aug-13-19 04:03AM  
Jul-31-19 04:14AM  
Jul-26-19 04:20AM  
Jul-01-19 09:00AM  
Jun-04-19 08:00AM  
May-31-19 03:15AM  
May-10-19 04:15AM  
May-06-19 09:00AM  
Apr-29-19 05:02AM  
Mar-29-19 12:13PM  
05:50AM  
Mar-28-19 10:41AM  
Mar-22-19 07:25AM  
Mar-11-19 03:00AM  
Feb-26-19 05:35PM  
Jan-29-19 05:40PM  
Jan-23-19 01:35AM  
Jan-14-19 06:34PM  
05:44PM  
09:46AM  
Jan-13-19 05:30PM  
Jan-04-19 02:00AM  
Jan-02-19 03:48AM  
Dec-02-18 12:00PM  
Nov-27-18 04:47AM  
Nov-20-18 05:00AM  
Nov-08-18 06:05AM  
Nov-01-18 10:20AM  
Oct-30-18 03:54AM  
Oct-22-18 07:00AM  
Oct-17-18 12:31PM  
Oct-09-18 06:15AM  
Sep-21-18 04:00AM  
Sep-17-18 06:58AM  
Sep-04-18 02:47AM  
Aug-20-18 02:49AM  
Aug-10-18 08:19AM  
Aug-06-18 04:05AM  
Jul-03-18 04:01AM  
May-30-18 01:47PM  
08:35AM  
May-17-18 02:25AM  
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, and HER2, as well as gastric cancer. Its Varlitinib completed a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, the company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.